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Inverse optimization of robotic stereotactic lung radiotherapy is typically performed 
using relatively simple dose calculation algorithm on a single instance of breathing 
geometry. Variations of patient geometry and tissue density during respiration could 
reduce the dose accuracy of these 3D optimized plans. To quantify the potential 
benefits of direct four-dimensional (4D) optimization in robotic lung radiosurgery, 
4D optimizations using 1) ray-tracing algorithm with equivalent path-length hetero-
geneity correction (4EPLopt), and 2) Monte Carlo (MC) algorithm (4MCopt), were 
performed in 25 patients. The 4EPLopt plans were recalculated using MC algorithm 
(4MCrecal) to quantify the dose prediction errors (DPEs). Optimization convergence 
errors (OCEs) were evaluated by comparing the 4MCrecal and 4MCopt dose results. 
The results were analyzed by dose-volume histogram indices for selected organs. 
Statistical equivalence tests were performed to determine the clinical significance 
of the DPEs and OCEs, compared with a 3% tolerance. Statistical equivalence tests 
indicated that the DPE and the OCE are significant predominately in GTV D98%. 
The DPEs in V20 of lung, and D2% of cord, trachea, and esophagus are within 1.2%, 
while the OCEs are within 10.4% in lung V20 and within 3.5% in trachea D2%. The 
marked DPE and OCE suggest that 4D MC optimization is important to improve 
the dosimetric accuracy in robotic-based stereotactic body radiotherapy, despite 
the longer computation time.  
PACS numbers: 87.53.Ly, 87.55.km
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I. IntroductIon
Inverse optimization of intensity-modulated stereotactic body radiotherapy (IM-SBRT) is typi-
cally performed using conventional ray-tracing or pencil beam (PB) convolution algorithms 
with radiological equivalent path length (EPL) for tissue heterogeneity during the optimization 
stage and in the final dose calculation.(1-4) Numerous studies have demonstrated the deficiency 
of these algorithms to predict the tumor dose distribution in low-density regions such as thorax, 
with the largest discrepancies observed at the tissue–lung interfaces due to serious lateral elec-
tronic disequilibrium.(1,5) It can be expected that when the set of “optimized” IM-parameter (e.g., 
beamlets weight and beam orientation) derived from conventional dose calculation algorithms 
is applied to obtain the final dose distribution using a gold standard method (e.g., Monte Carlo 
algorithm), the resultant dose distribution and relevant target dose constraints will be nowhere 
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close to the initially optimized ones. The difference between the PB/ray-tracing algorithms and 
the MC algorithm contributes to systematic dose prediction error (DPE). When these algorithms 
are employed during inverse optimization, optimization convergence error (OCE) occurs because 
the DPE causes the optimizer to converge to suboptimal solution.(6) 
For lung SBRT, inverse optimization is further complicated concerning the temporal changes 
of patient anatomy. As the patient breathes, the lung expands and compresses resulting in varia-
tion of density within each lung voxel to conserve lung mass. Jin et al.(7) have investigated 
the relationship between beam margin and the lung density. They suggested that either the 
beam margin or the prescription level had to be varied in order to maintain the desired dose 
coverage with the lung density changing. The fact that dose optimization is typically done on a 
single CT scan and uses a constant margin implies the prescription dose level is not guaranteed 
optimized in terms of target dose coverage and other normal tissue constraints throughout the 
breathing cycle. 
Four-dimensional (4D) dose calculation is a powerful tool to explicitly include the effect 
of organ motion. The general approach of 4D dose calculation is to employ deformable vector 
fields obtained from deformable image registrations to warp dose distributions calculated on 
different breathing geometries to a reference geometry so that the cumulative effect of organ 
motion can be accounted for. So far, 4D dose calculation has been predominately performed 
outside the commercial treatment planning systems, and is mostly employed as a tool for assess-
ing, rather than including, the cumulative effect of organ motion and deformation. Starkschall 
et al.(8) applied standard 3D plans created on one single breathing instance to other breathing 
instances and deformably summed these independent dose distributions to compose the 4D 
dose distribution. They showed that 4D dose calculation has the potential to detect unexpected 
decrease of tumor dose and increase of organs-at-risk (OAR) doses. Four-dimensional dose 
calculation frameworks of similar kind are valuable in terms of evaluating the dosimetric impacts 
of organ motion, but do not help to avoid violations of dose constraints as specified in the plans 
that are optimized on the static 3D CT images. A few investigators have taken the logical step to 
extend the capability of 4D dose calculation to build different frameworks of 4D dose optimi-
zation in conventional linac-based intensity-modulated radiotherapy (IMRT).(9-11) Despite the 
theoretical advantages of 4D MC optimization (4D MCO), MultiPlan of CyberKnife remains 
the sole commercial treatment planning system (TPS) that supports direct 4D optimization in 
SBRT. To date, no results have been reported the potential benefits of 4D MCO in real-time 
tumor tracking SBRT using CyberKnife. In fact, 4D MCO is particularly useful to include this 
dynamic movement of treatment beam while taking into account of the dosimetric effects of 
breathing-induced geometry and density changes during plan optimization. The aim of this work 
is to investigate the potential advantages of direct four-dimensional (4D) MC optimization (4D 
MCO) to improve dose accuracy in robotic-based IM-SBRT. 
 
II. MAtErIALS And MEtHodS
A.  Patient selection and treatment planning
This study included a cohort of 25 lung cancer patients previously treated with CyberKnife 
(Accuray Inc., Sunnyvale, CA) (Table 1). Each patient had a four-dimensional computed tomog-
raphy (4D CT) scan. The 4D CT acquisition and reconstruction protocols were described in 
our previous study.(12) Each 4D CT study was reconstructed into ten equal time binned 3D CT 
images. All treatments were performed under real-time tumor tracking using either the Synchrony 
Respiratory Tracking System (RTS) (Accuray Inc.) or XSight Lung Tracking System (Accuray 
Inc.). Technical descriptions of these tracking methods were previously described by Kilby et 
al.(13) The lung tumors ranged in different sizes and locations. Characteristics of these tumors 
were described in Table 1. In this study, plans were designed to deliver either a total dose of 
60 Gy in three fractions or 48 Gy in four fractions to 95% of the planning target volume (PTV), 
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which was expanded by 5 mm from the gross tumor volume (GTV). Other planning objectives 
included sparing of normal lung tissue, cord, trachea, and esophagus. 
B.  dose calculation algorithms
The ray-tracing and Monte Carlo patient dose calculation algorithms available in the CyberKnife 
TPS MultiPlan v.4.0.x (Accuray Inc.) were used for the inverse optimization. These algorithms 
have been previously described and compared by different authors.(1,14,15) Briefly, the ray-tracing 
algorithm calculates dose by applying heterogeneity correction factors to scale the tissue phantom 
ratios of the measured broad beam data along beam central axis. Therefore, dose discrepancies 
may result from the assumption of charged particle equilibrium. The Monte Carlo dose engine 
is based on a single source model that describes the source distribution, energy distribution, 
and fluence distribution.(16) The MultiPlan TPS uses a piecewise algorithm to convert the 
CT numbers to mass density and material. Each voxel in the patient geometry is assigned a 
mass density ρ for scaling the mean free paths (MFPs) of photons, and the steps of electron 
and positron tracks through each voxel. A material type is also assigned to each voxel (air if 
ρ < 0.1 g/cc, soft tissue if 0.1 ≤ ρ ≤ 1.125, or bone if > 1.125) for defining the photon MPFs 
with each material type as a function of photon energy. The MC algorithm uses various variance 
reduction techniques (VRTs) including photon interaction forcing, photon splitting, employing 
Russian roulette, electron history repeating, and electron range rejection for efficient particle 
transports in the 3D rectilinear voxel geometry of the patient model. The VRTs implemented 
within this MC algorithm utilize a voxel model that considers various materials as being equiva-
lent to variable density water for the purpose of the electron transport calculations. Therefore, the 
resulting dose quantity from the electron transport algorithm is expressed in terms of absorbed 
dose to variable density water, which is virtually identical to conventional MC-calculated 
absorbed doses to media for most biological materials including lung and cortical bone.(17)  
c.  4d planning framework and 4d optimization schemes
Direct 4D inverse optimization was carried out with the 4D planning module in the MultiPlan 
TPS. The 4D planning architecture is illustrated in Fig. 1. As input, 4D CT images were needed 
for the construction of a patient breathing model. One of the core components of the 4D plan-
ning system is the dose mapping method that relates the dose deposition of each anatomic 
voxel between multiple samples of breathing geometry. Due to the notable tissue expansion 
and compression during respiration, a one-to-one correspondence between voxels of different 
breathing geometry generally does not exist. The MultiPlan TPS generated a series of voxel 
correspondence maps or deformation vector fields (DVFs) using a B-spline deformation image 
registration (DIR) algorithm.(18) In the 4D planning module, image registration was carried 
Table 1. Tumor characteristics.
Total Patient Number 25
Gross Tumor Volume (cc) 
 Median 10.2
 Range 0.6-77.4
Planning Tumor Volume (cc) 
 Median 27.8 
 Range 4.2-134.5
Principal Motion Amplitude (mm) 
 Median 7.0
 Range 1.0-22.5
Tumor Location 
 Upper lobe 4 (16%)
 Middle lobe 17 (68%)
 Lower lobe 7 (28%)
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in a two steps.(18) First, rigid registrations were performed to estimate locations of the target 
at different time point over the breathing cycle and served as the basis for shifting the beam 
aperture to reflect the target motion.(19) In the second step, a dual resolution hybrid point and 
intensity-based approach of deformable image registrations was used to produce deformation 
vector fields (DVFs) that were calculated between adjacent images in the 4D CT study. Results 
of the evaluation of this DIR algorithm were referred to Stancanello et al.(20) The resultant 
DVFs were then applied to accumulate the dose distributions calculated at different respira-
tory states back onto the reference dose grid of the end-of-exhale (EOE) state to compose the 
4D dose distribution. During optimization, the 4D dose matrix was continuously updated at 
 
FIG. 1. Illustrations of the 4D planning architecture, and the 4D optimization schemes: 1. 4D 
optimization using quivalent path-length (EPL) dose calculation algorithm, and 2. 4D optimization 
using Monte Carlo dose calculation algorithm. The dashed lines indicated the dose prediction error, 
quantified by the difference between 4EPL
opt
 and 4MC
recal
 methods, and the optimization convergence 
error (OCE), quantified by difference between 4MC
recal
 and 4MC
opt
.  
 
Fig. 1. Illustrations of the 4D planning architecture and the 4D optimization schemes  using equivalent path-length (EPL) 
dose calculation algorithm and using Monte Carlo dose calculation algorithm. The dashed lines indicated the dose predic-
tion error, quantified by the difference between 4EPLopt and 4MCrecal methods, and the optimization convergence error 
(OCE), quantified by difference between 4MCrecal and 4MCopt. 
186  chan et al.: Errors in 4d optimization of lung SBrt 186
Journal of Applied clinical Medical Physics, Vol. 14, no. 4, 2013
each optimization step and displayed on the reference CT frame in which all structure contours 
were defined. 
In this study, two 4D optimizations were run for each 4D CT scan (Fig. 1), first with the con-
ventional ray-tracing algorithm with equivalent path length heterogeneity correction (4EPLopt), 
and then restarted with the Monte Carlo dose engine (4MCopt). All optimizations were carried 
out using the sequential optimization algorithm. The sequential algorithm was executed in a 
series of optimization steps, each of which performs a simplex optimization applied to a single 
objective cost function designed to correspond to a specific clinical objective (e.g., target dose 
conformity, target dose coverage, maximum/mean dose to critical organs).(21) The initial number 
of beams available to solution space depended on the number of predefined circular aperture(s) 
(approximately 2000 and 3000 beams for two and three circular collimators, respectively). To 
eliminate biases introduced by the planner, both optimizations were carried out with the same 
set of planning objectives that were determined from a large number of test cases. Considering 
that a significant amount time was needed to calculate the dose distributions on different patient 
geometries and to update the 4D dose matrix upon dose accumulation on the reference grid, 
the 4D MCO was performed in a medium resolution grid (~ 2.1 × 2.1 × 1.25 mm3) and with 
4% statistical uncertainty σ at the maximum dose point (Dmax). For evaluations of the dose 
prediction and optimization convergence errors, all 4EPLopt plans were recalculated with the 
MC dose engine, yielding the 4MCrecal plans. All final MC dose distributions were calculated 
using high resolution grid (~ 1.05 × 1.05 × 1.25 mm3) and at 1% statistical uncertainty. For the 
present work, the time required to come up with a reasonable 4MCopt plan varied from seven to 
more than 12 hours on the current system (Intel Xeon Processor 3.00 GHz), depending on the 
number of apertures and treatment beams in question. Note that this excluded the time spent 
on structure contouring and dose distribution fine-tuning.
E.  dosimetric evaluations
Dosimetric evaluations were performed by analyzing the dose-volume histograms (DVHs). The 
DVH indices of given tissues DV (Gy) and VD (%) are equal to the dose level D (Gy) covering 
volume V (%), and the volume V (%) covered by a given dose level D (Gy), respectively. The 
evaluated DVH indices included GTV D98%, cord D2%, esophagus D2%, trachea D2%, and lung 
V20 Gy. The D98% and D2% indices are recommended as surrogates of the minimum dose and 
maximum dose in the ICRU Report 83.(22) In addition, the D98% and D2% are less susceptible 
to statistical fluctuations in MC dose calculations, as suggested by Sakthi et al.(23) 
As previously mentioned in the Introduction, the dose prediction error (DPE) due to EPL 
algorithm will be defined as the difference of dose result between the 4EPLopt plan and the 
4MCrecal plan that was obtained by recalculating the 4EPLopt plan with the MC dose engine 
(Fig. 1). The DPE reflects differences introduced by variations of patient tissue heterogeneity 
during respiration. Considering the MC algorithm as the gold standard, the DEP is quantified 
by comparing DVH indices as: 
 
  (1)
or 
     
  (2)
On the other hand, the optimization convergence error (OCE) due to the EPL algorithm is 
defined as the difference of dose result between plans optimized with the MC algorithm (i.e., 
4MCopt) and the EPL algorithm (4EPLopt). The OCE source addressed by this work is the 
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accuracy of the dose calculations employed during the optimization process (Fig. 1). Similar 
to Eq. (1) and Eq. (2), the OCE is quantified by comparing DVH indices as:
  (3)
 or 
      
  (4)
In evaluating the DPEs and OCEs, DVH indices from the 4MCrecal and 4MCopt solutions were 
taken as references, respectively. As pointed out in the AAPM Report 65, a dose calculation 
accuracy of 2%–3% is required to achieve an overall uncertainty of .(24) Therefore, a 3% 
difference from the reference DVH indices was considered clinical significant. Furthermore, 
the equivalent test method was adopted to determine the minimum DV (Gy) or VD (%) intervals 
around the reference 4MCrecal and 4MCopt values such that t-tests concluded that the reference 
and test DV (Gy) or VD (%) values in the DPE and OCE evaluations were equivalent with p < 
0.05.(25) In brief, the DV or VD intervals around the reference 4MC
recal and 4MCopt values were 
initially set to zero. They were then increased in 0.01 Gy steps until results of the paired t-tests 
indicated equivalence between the 4EPLopt and 4MCrecal solutions, and between the 4MCrecal 
and 4MCopt solutions with p-values > 0.05 in the DPE and OCE evaluations, respectively. The 
percentage of the DV or VD intervals with respect to the averaged reference DVH values of 
each structure were then compared with 3% to determine if the DV or VD intervals of the DPE 
were clinically significant. Similarly, the equivalent test was performed to determine the clinical 
significance of OCE for each structure. 
 
III. rESuLtS 
Figure 2 shows the DPEs of different DVH indices for each patient. Note that the patient number 
was ordered in ascending GTV size. The results were normalized to  or  to facilitate 
intercomparisons between patients receiving different prescription doses. Notable differences 
occur in the GTV D98%, indicating that the 4EPL
opt method overestimated the GTV D98% by a 
factor of 1.13, on average, and up to 1.36 in one patient. The DPE in GTV D98% increases with 
decreasingly GTV size (Spearman’s rank correlation coefficient r = -0.61). The 4MCrecal solu-
tions systematically underpredict the OAR doses as the majority of points are above the line 
of unity. The maximum DPE in D2% varies between spinal cord, esophagus, and trachea from 
1.54 to 1.78, and the DPE in V20Gy varies from 0.61 to 1.34 for lung. Of the underpredicted 
DVH indices, none of them violates their respective dose constrains. The magnitude of DPEs 
is considerable for only 22 out of the 125 analyzed DVH indices are within ± 3% threshold. 
Of these 22 indices, four are in the GTV and the other 18 are in the OARs. 
The statistical results are given in Table 2. The first column of the table shows the averaged 
values of the reference DVH indices over 25 patients. The following column shows the DV 
(Gy) or VD (%) intervals at which equivalence tests indicated DPEs are statistically significant. 
The DPE is statistically significant only in the GTV, as the D98% interval around the 4MC
recal 
reference value is outside 3% tolerance. For OARs, although the DVH indices are outside the 
± 3% threshold in 82 out of the 100 DVH indices, the D2% and V20Gy intervals around their 
corresponding reference of 4MCopt averages are within 0%–1.2%. Thus, the DPEs in OARs 
are clinically insignificant. The 4EPLopt and 4MCrecal dose distributions in the axial and coronal 
planes of a 73.8 cc GTV are shown in Fig. 3. These dose distributions are similar in the low-
to-medium dose volume, but exhibit observable systematic dose prediction error at the GTV 
interface with the low-density lung tissue. The difference between the two types of errors are 
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further exemplified in Fig. 4(a) and 4(b). In Fig. 4(a), the 4EPLopt plan undergoes the final dose 
calculation using two different dose calculation algorithms (EPL and MC). Consider that MC 
dose calculation is the gold standard, the 4EPLopt DVHs exhibits a systematic dose predic-
tion error. In Fig. 4(b), the same final dose calculation algorithm was used (MC), but the dose 
algorithms used in optimization differed. The differences in DVHs between the 4MCrecal and 
4MCopt solutions demonstrate an optimization convergence error.    
 
FIG. 2. Normalized DVH indices resulting from comparison of 4EPL
opt
 with 4MC
recal
 for different 
organs. The differences quanti y the magnitude of DPEs. The dotted lines indicate the 3% tolerance and 
the solid line indicates the baseline when the dos  prediction errors are nil. The patient number was 
ordered with ascending GTV size.  
Fig. 2. Normalized DVH indices resulting from comparison of 4EPLopt with 4MCrecal for different organs. The differences 
quantify the magnitude of DPEs. The dotted lines indicate the 3% tolerance and the solid line indicates the baseline when 
the dose prediction errors are il. The patient number was ordered with ascending GTV size. 
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Results of the per-patient OCE evaluation are presented in Fig. 5. It can be observed that 
the OCE plots roughly mirror the corresponding DPE plots. The 4MCopt method corrects both 
under- and overpredicted GTV D98%. For OARs, the majority of normalized DVH indices are 
smaller than unity, suggesting that the final solutions of the 4MCopt method in sparing the OARs 
approach to those of the 4EPLopt method. Averages of the normalized D2% vary from 0.90 for 
cord, 1.00 for esophagus, and 1.05 for trachea, and the normalized V20Gy of lung varies from 
Table 2. Statistics results of different DVH indices, and the DV (Gy) and VD (%) intervals at which statistical 
equivalence test indicate that DPEs (4EPLopt vs. 4MCrecal) and OCEs (4MCrecal vs. 4MCopt) are statistically significant 
(p <0.05) for each DVH index analyzed.
 Average 4MCrecal   Average 4MCopt
 DV (Gy) or VD (%)  DV (Gy) or VD (%) 
 used as DPE DPE Interval of used as OCE OCE Interval of
 Reference DV (Gy) or VD (%) Reference Dv (Gy) or VD (%) 
GTV D98% 6000 cGy 1044 cGy 6821 cGy 1188 cGy
Cord D2% 992.7 cGy 7 cGy 1093 cGy 15 cGy
Trachea D2% 804 cGy 10 cGy 849 cGy 30 cGy
Esophagus D2% 951 cGy 5 cGy 1024 cGy 20 cGy
Lung V20Gy 5% 0.0% 6.4% 0.7%
4MCrecal = the ray-tracing optimized 4D plan (4EPLopt) recalculated by Monte Carlo; 4MCopt = direct 4D Monte 
Carlo optimized plan; DPE = dose prediction error; OCE = optimization convergence error; Dv = dose received by V 
percentage volume of the OAR; VD = percentage volume receiving at least dose D.
 
FIG. 3. The 4EPL
opt
 and 4MC
recal
 dose distributions are shown in the axial (left column) and 
coronal (right column) for a 73.8 cc tumor located in the right middle lobe of the lung. The most 
pronounced difference between these distributions is observed in the rescription dose level of 60 Gy 
that falls short of covering the planning target volume (outlined by the blue solid line) after 4EPL
opt
 
solution was applied to the 4MC
recal
 method.  
 
Fig. 3. The 4EPLopt and 4MCrecal dose distributions are shown in the axial (left column) and coronal (right column) for 
a 73.8 cc tumor located in the right middle lobe of the lung. The most pronounced difference between these distributions 
is observed in the prescription dose level of 60 Gy that falls short of covering the planning target volume (outlined by the 
blue solid line) after 4EPLopt solution was applied to the 4MCrecal method. 
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0.55 to 1.30, with a mean of 0.80. Figure 5 shows that the 4MCopt method reduced cord D2% to 
below 18 Gy dose limit in two patients who had their cord D2% exceeded 18 Gy in the 4MC
recal 
plans. It is noteworthy that there was also one case where the 4MCrecal solution yielded cord 
D2% < 18 Gy, whereas the 4MC
opt method came up with a solution ensuring the PTV but failed 
to meet the cord dose tolerance. The OCE is within the 3% tolerance level in ten out of the 
125 analyzed DVH indices, of which only one is in the GTV. Statistical results of the averaged 
4MCopt doses and the corresponding DV or VD intervals are given in the third and fourth columns 
in Table 2. Since the percentage of D98% interval in GTV is 17.4%, which is greater than the 
relative uncertainty level (< 5%), the OCE due to the EPL algorithm is definitely significant. 
Table 2 also demonstrates that the results of statistical tests differ between OARs. Statistical 
equivalences were observed in the D2% intervals of cord, trachea, and esophagus within 3.5% 
of the reference 4MCopt doses. For lung, a statistical equivalence was observed in the V20Gy 
interval within 10.4% of the reference 4MCopt V20Gy. 
Figure 6 shows dose difference maps between the 4MCrecal and 4MCopt dose distributions. 
The hot and cold spots seen in the dose difference maps indicate that the 4MCopt solution 
not only manages to compensate the dose loss caused by out-scattering electrons not being 
replaced by in-scattering electrons in the low-density lung tissues at the posterior, medial, and 
 
FIG. 4. Dose volume histograms of the GTV and PTV, and selected critical organs exemplify the 
two types of errors (a) dose prediction errors and (b) optimization convergence errors. (4a) 
demonstrates the dose differences when the 4EPL
opt
 plan undergoes the final dose calculation using two 
different dose calculation algorithms (EPL and MC) whereas (4b) shows the dose differences when the 
same final dose calculation algorithm (MC) is used but the dose algorithms used in optimization differ 
(EPL and MC).  
Fig. 4. Dose-volume histograms of the GTV and PTV, and selected critical organs exemplify the two types of errors: dose 
prediction errors and ptimization convergence errors. he dose differences (a) when the 4EPLopt plan undergoes the final 
dose calculation using two different dose calculation algorithms (EPL and MC); the dose differences (b) when the same 
final dose calculation algorithm (MC) is used but the dose algorithms used in optimization differ (EPL and MC). 
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craniocaudal side of the GTV, but also lowers doses in the chest wall on the other side. It is 
also noteworthy that the 4MCopt solution sometimes causes higher normal tissue dose, pos-
sibly due to the increased monitor units (MU) required to compensate to electron losses in the 
low-density GTV-to-PTV regions. 
The relative statistical dose uncertainty maps in Fig. 7(a) and 7(b) highlight the difficulties 
of evaluating and reporting doses for different structures. The relative dose uncertainties are 
up to 7% in cord and even higher in the contralateral lung, which receives relatively low doses 
 
FIG. 5. Normalized DVH indices for different organs demonstrating the effects of 4MC
opt
 method. 
Differences are resulted from the OCEs when 4MC
recal
 and 4MC
opt
 methods are compared. The solid 
and dotted lines are the same as in FIG. 2.  
Fig. 5. Normalized DVH indices for different organs demonstrating the effects of 4MCopt method. Differences are resulted 
from the OCEs when 4MCrecal and 4MCopt methods are compared. The dotted lines indicate the 3% tolerance and the solid 
line indicates the baseline when the dose prediction errors are nil.
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(Note: relative percentage uncertainty in dose per voxel ).(26) This uncertainty is 
comparable to, and sometimes greater than, the percent DV or VD intervals, thus confounding 
the results of the statistical equivalence tests.        
 
IV. dIScuSSIon & concLuSIonS
The use of 4D CT and deformation image registration made it possible to quantify the effects 
of DPEs and OCEs due to differences between conventional ray-tracing and accurate Monte 
Carlo dose calculation methods in deforming geometry that have not been previously studied 
in robotic-based lung SBRT. Our results demonstrated that conventional ray-tracing correction-
based algorithm failed to account for the lateral electron disequilibrium. As a consequence, the 
4EPLopt solution systematically overestimated the GTV D98% (Fig. 2). Notably, there is system-
atic clipping of the PTV by the prescription isodose line in the low-density rind surrounding the 
GTV (Fig. 3). In this work, a 17.4% dose interval is required to encompass the DPE in GTV 
D98%, which was considered clinically significant based on the 3% tolerance (Table 1). For the 
selected OARs, the DPE was found in the range of 3.5% to 8.6%. These results were consis-
tent with other studies that quantified the DPEs in static 3D geometries. For instance, van der 
 
FIG. 6. Dose difference maps in the axial (a) and coronal (b) planes for patient 23. They were 
obtained by subtracting the 4MC
recal
 doses from the 4MC
opt
 doses. It shows the 4MC
opt
 solution 
manages to attain adequate dose coverage of the PTV medially and posteriorly while lowers excessive 
dose in portion of the chest wall.    
 
 
FIG. 7. Statistical dose uncertainty between different anatomic regions in the 4MC
recal
 (a) and 
4MC
opt
 dose results (b). The red and orange solid lines indicate the gross tumor volume and the 
planning target volume, respectively. 
 
Fig. 6. Dose difference maps in the axial (a) and coronal (b) planes for patient 23. They were obtained by subtracting the 
4MCrecal doses from the 4MCopt doses. The figure the 4MCopt solution manages to attain adequate dose coverage of the 
PTV medially and posteriorly while it lowers excessive dose in portion of the chest wall.   
Fig. 7. Statistical dose uncertainty between different anatomic regions in the 4MCrecal (a) and 4MCopt dose results (b). The 
red and orange solid lines in icate the gross tumor volume and the pl ning target v lume, respectively.
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Voort van Zyp et al.(1) recalculated 53 patient plans optimized with ray-tracing algorithm by the 
same Monte Carlo algorithm as used in this study and reported an averaged decrease of PTV 
prescription dose coverage by 21% in tumors < 3 cm and 10% in tumors > 5 cm. For OARs, 
they reported DPEs of 7% and 6% in maximum doses of cord and esophagus, respectively. 
Through incorporation of MC dose calculation in 4D optimizations, the 4MCopt solutions 
eliminated the OCEs of the 4EPLopt that caused the PTV to look as if it were covered adequately 
by the prescription dose, but was indeed seriously underdosed. The 4MCopt solutions ensured 
adequate PTV coverage, while effectively constrained the GTV dose in excess of that pre-
scribed. This is reflected in the same GTV D98% interval required to encompass the OCE and 
the DPE. In Fig. 7, the statistical uncertainty in the GTV was found to be within 5% and was 
smaller than the 17% dose interval of GTV D98%. Therefore, the OCE was confirmed clinically 
significant. The OCEs differed between OARs. The percent dose interval D2% varied from 1.3% 
for cord to 3.5% for trachea, and for lung within 10.4% of the averaged V20Gy. As shown in 
the OCE plots (Fig. 5), the 4MCopt solutions result in a slight increase of DVH index values 
in different OARs. Intuitively, the direct inclusion of OAR constrains in the MC optimization 
should make available previously unexplored solution space for improvement of the OAR 
doses. As mentioned in earlier session, the objective parameters were not optimal for individual 
patients because they were derived from a large number of test cases. When the optimization 
sequence was such that it always prioritized maximization of the PTV dose coverage and the 
PTV minimum dose, the solution space available beyond these steps for further optimizations 
of OARs’ doses became smaller. In addition, doses of the OARs after these steps were in most 
occasions much less than the clinical objectives defined in the optimization sequence. Thus, the 
OAR optimization steps were simply skipped without refined objective inputs. For the patient 
whose cord D2% exceeded the dose limit 18 Gy in the 4MC
opt solution, it is expected that set-
ting tighter maximum dose constraint or reordering the optimization sequence shall reduce the 
cord D2% below the dose limit. 
Although the OCEs were statistically significant for a few OARs, the percentage of DV and 
VD intervals were comparable to the statistical dose uncertainty. In fact, statistical fluctuations 
contributed to noise convergence error of the 4MCopt solution which propagated from one opti-
mization step to the next. The noise convergence error was introduced because the optimization 
converged to an “optimal” solution of beam weights that was difference from the actual optimal 
one in a noise-free dose distribution. In beamlet-based MC optimization, the noise convergence 
error was related to the number of simulated particle histories of the MC beamlets and became 
significant when the statistical uncertainty of the MC beamlets was of the order of 2%.(27,28) 
Jeraj and Keall(28) showed that the noise convergence error approximately follows the statisti-
cal error. Based on the result of Jeraj and Keall, we expect that the relatively large statistical 
uncertainty (4%) could cause some deviation of the solution of 4D MCO from the optimal one. 
We aim to investigate the tradeoff between noise convergence error and computation time in 
4D MCO of robotic SBRT in future work. 
There have been questions about the reliability of deformation image registration for map-
ping dose calculated at different breathing geometries to the reference geometry. The effect 
of applying deformation vectors is to deform voxels of the reference phase image to other 
individual phase images. In case of large deformation, the remapped undeformed reference 
dose voxels do not necessarily overlap with the voxels of the dose grids of other breathing 
phases from which doses are to be remapped. This introduces voxel-size dependent interpola-
tion error.(29)  Furthermore, the deformation image registrations employed in the CyberKnife 
MultiPlan TPS were based on a simple voxel warping approach without congruent energy and 
mass mapping. Heath et al.(30) have previously investigated the deformation models defVox 
and its variation defTetra with and without energy and mass mapping using the VMC++ Monte 
Carlo code. They suggested that consistent mass and energy mapping methods were essential 
to get meaningful results in situations where inexact deformation fields were used to provide 
the geometrical transformation. Nonetheless, the defVox model with energy and mass mapping 
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requires long calculation time. Therefore, the deformation registration model implemented on 
the MultiPlan TPS may still be considered the most clinically practical approach to estimate 
the dose in deforming geometries.
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